NCT04016753View on ClinicalTrials.gov

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

February 21, 2020

Study Completion Date

February 21, 2020

Conditions
Healthy Participants
Interventions
DRUG

BMS-986256

30 mg(6ml)

DRUG

Loestrin

1.5 mg Norethindrone and 30ug ethinyl estradiol

Trial Locations (1)

90630

Altasciences Los Angeles (Formerly WCCT Global), Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY